Table 3. Analysis of the risk factors for clinical outcome after inclusion of copy number losses as new parameters.
| Univariate analysis | PFS | OS | Multivariate analysis | PFS | OS | ||
|---|---|---|---|---|---|---|---|
| P | P | HR (95% CI) | P | HR (95% CI) | P | ||
| CD58 mutation | 0.004 | 0.03 | COO (non-GCB) | 1.86 (1.00-3.45) | 0.048 | 2.80 (1.29-6.09) | 0.009 |
| TP53 mutation | 0.03 | 0.011 | B symptoms | 2.07 (1.17-3.67) | 0.012 | 1.98 (1.03-3.79) | 0.04 |
| Ann Arbor stage III/IV | 0.026 | 0.05 | CD58 mutation | 3.85 (1.61-9.18) | 0.002 | 4.72 (1.74-12.80) | 0.002 |
| COO (non-GCB) | 0.033 | 0.024 | TP53 mutation | 3.07 (1.52-6.19) | 0.002 | 4.94 (2.15-11.32) | < 0.001 |
| B symptoms | 0.019 | 0.04 | CNVs of CD58 | 2.61 (1.22-5.56) | 0.013 | NS | NS |
| MYC aberration | 0.016 | 0.158 | CNVs of TP53 | 2.54 (1.19-5.42) | 0.016 | 3.87 (1.70-8.81) | 0.01 |
| BM involvement | 0.036 | 0.012 | |||||
| CNVs of CD58 | 0.002 | 0.11 | |||||
| CNVs of TP53 | < 0.001 | < 0.001 | |||||
Abbreviations: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival